LYCOS RETRIEVER 
Requip
built 655 days ago
The recommended starting dose of Requip (Ropinirole) is 0.25 mg three times daily. The Requip (Ropinirole) dosage should then be gradually increased in weekly increments of 0.25 mg per dose to reach a daily dose of 1 mg three times daily. Based on individual patient response,Requip (Ropinirole) dosage may be increased by 0.5 to 1.0 mg per dose on a weekly basis to a maximum daily dose of 24 mg. When Requip (Ropinirole) is administered as adjunctive therapy with levodopa, the concurrent dose of levodopa may be decreased gradually by 20 percent on average. Requip (Ropinirole) will be available within the next few weeks for both initial therapy and adjunctive therapy with levodopa in 0.25 mg, 0.5 mg, 1 mg, 2 mg or 5 mg tablets. Requip (Ropinirole),unlike levodopa, does not need to be converted to dopamine and is immediately available to act on dopamine receptors. Clinical studies have shown that using Requip (Ropinirole) early in Parkinson's disease effectively controls motor symptoms, thereby delaying the use of levodopa.
Source:
The currently marketed formulation of Requip Tablets is indicated in the U.S.for the treatment of the signs and symptoms of idiopathic Parkinson’s disease and is administered three times a day. Prescription Requip is not for everyone. Requip may cause patients to fall asleep or feel sleepy during normal activities such as driving; or to faint or feel dizzy, nauseated, or sweaty when they stand up. Patients should tell their doctor if they experience these problems or if they drink alcohol or are taking other medicines that make them drowsy. Patients should ... tell their doctor if they experience new or increased gambling, sexual, or other intense urges while taking Requip. Hallucinations may occur at anytime during treatment.
Source:
Use Requip with caution if you have heart disease. There is ... a slight chance of developing respiratory difficulties or problems with your eyesight. If you find it hard to breathe, have any swelling, or develop problems with your vision, alert your doctor at once.
Source:
Requip was generally well-tolerated. In the majority of patients, adverse events were generally mild and included sedation, nausea, fatigue, dyspepsia, shoulder pain, acne and hypomania. Three patients discontinued the therapy because of side effects. As recommended for patients with Parkinson's disease, all patients should be informed that syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Hallucinations can occur at any time during the course of treatment with dopamine agonists such as Requip. Further clinical trials will need to be conducted to determine if these adverse events will occur in patients with RLS.
Source:
The side effect that may be found when using Requip will always vary upon the user. All drugs have side effects that will range from small complications such as weight gain or weight loss to sleep deprivation. As the side effects with Requip will range from individual to individual we recommend that if you suspect any danger or possible overdose that you contact and seek medical attention from your local emergency clinic or in less severe cases phone your physician. For the best information on current drug side effects it is always best to go online to a news forum for recent info and reviews of the possible side effects, warnings and dangers of Requip. To decrease the risks involved with any drug it is always best to follow a healthy lifestyle, take the correct dosage at the proper time and always follow the instructions on communicated to you by the pharmacist or doctor about how to take Requip. When a drug is administered by a doctor or a pharmacist they are required to communicate with you the proper dosage and ... tell you about the possible side effects.
Source:
Requip® XL 24-hour™ (ropinirole) for Parkinson’s disease was developed in partnership with GlaxoSmithKline. A recent study showed that adding Requip® XL 24-hour™ ropinirole prolonged release tablets to Parkinson’s disease patients’ existing levodopa therapy significantly reduced the “off” time by an average of more than two hours per day when compared with baseline prior to treatment... allowing patients to continue their daily activities for a longer period of time. In addition, the 24 hour dosing regime should significantly aid compliance. It was filed for approval at the end of 2005 in Europe, and regulatory approval was received in France in April 2007. It also has approval in Canada, Slovakia, Slovenia, Latvia and Estonia and GlaxoSmithKline plans to gain further marketing authorizations in other member states of the European Union. The US NDA was submitted in February 2007, and the US FDA accepted the submission for filing in April 2007.
Source:
MORE ABOUT
Requip